Table 3. Demographic and clinical characteristics of patients in the NS and LN groups.
| Variables | NS (N=108) | LN (N=100) | t/χ2 value | P-value |
| Data are presented as mean±SD, except for the data on gender and anti-Sm antibody and anti-dsDNA antibody positive rate. NS: nephritic syndrome; LN: lupus nephritis; T-Cho: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Lp(a): lipoprotein(a); ApoA: apolipoprotein A; ApoB: apolipoprotein B; A/G: albumin/globulin; BUN: blood urea nitrogen; SCr: serum creatinine; Cys-C: cystatin C; CCR: creatinine clearance rate; UA: uric acid; MA: microalbuminuria; MA/UCr: MA/urine creatinine; Fib: fibrinogen; hsCRP: high-sensitivity C-reactive protein; T4/T8: CD4+ to CD8+ T cells ratio. | ||||
| Male [n (%)] | 60 (55.56) | 13 (13.00) | 84.200 | <0.001 |
| Age (years) | 46.45±18.68 | 40.82±13.79 | −2.895 | 0.004 |
| T-Cho (mmol/L) | 7.21±3.04 | 5.07±1.55 | −0.631 | 0.529 |
| TG (mmol/L) | 2.48±1.62 | 1.96±0.96 | 1.336 | 0.183 |
| HDL-C (mmol/L) | 1.81±0.73 | 1.48±0.55 | −3.250 | 0.001 |
| LDL-C (mmol/L) | 4.18±2.20 | 2.79±1.13 | −4.82 | <0.001 |
| Lp(a) (mg/L) | 410.88±392.15 | 294.15±310.48 | −1.755 | 0.081 |
| ApoA (g/L) | 1.57±0.63 | 1.34±0.37 | −2.608 | 0.010 |
| ApoB (g/L) | 1.37±0.63 | 0.90±0.36 | −5.182 | <0.001 |
| A/G | 1.29±0.47 | 1.51±0.44 | 2.534 | 0.012 |
| BUN (mmol/L) | 8.91±6.20 | 10.16±8.48 | 1.220 | 0.224 |
| SCr (μmol/L) | 109.37±90.96 | 135.21±140.41 | 1.582 | 0.115 |
| Cys-C (mg/L) | 1.63±1.17 | 1.87±1.22 | 1.365 | 0.174 |
| CCR (mL/minute) | 66.95±26.19 | 64.85±46.88 | −0.389 | 0.698 |
| UA (μmol/L) | 408.08±122.77 | 402.37±162.85 | −0.285 | 0.776 |
| MA (mg/L) | 5212.46±7287.50 | 1819.57±3357.35 | −3.793 | <0.001 |
| MA/UCr (mg/g) | 3237.29±3670.86 | 2400.72±5912.72 | −1.138 | 0.257 |
| Fib (g/L) | 4.18±1.64 | 3.40±1.23 | −3.282 | 0.001 |
| D-dimer (mg/L) | 3.31±4.19 | 3.22±6.50 | −0.092 | 0.927 |
| hsCRP (mg/L) | 21.15±57.17 | 1.45±2.30 | −3.373 | 0.001 |
| Anti-Sm antibody positive [n (%)] | 1 (0.90) | 27 (27.00) | 27.046 | <0.001 |
| Anti-dsDNA antibody positive [n (%)] | 2 (1.90) | 31 (31.00) | 32.346 | <0.001 |
| CD3+CD4+CD8− (%) | 34.18±10.47 | 32.15±8.89 | −0.510 | 0.135 |
| CD3+CD4−CD8+ (%) | 27.58±10.31 | 37.00±10.50 | 6.525 | <0.001 |
| CD3+CD4+CD8+ (%) | 0.53±0.36 | 0.84±0.91 | 3.240 | 0.001 |
| CD3+CD4−CD8− (%) | 3.29±2.11 | 3.55±2.45 | 0.816 | 0.415 |
| T4/T8 | 1.52±1.03 | 0.99±0.60 | −4.446 | <0.001 |